Integrating Personalized Medicine into Healthcare: Progress and a Path Forward
Introductory Stage Setting Presentation:
Featured Speaker: Elissa Quinn, Director, Precision Medicine, Blueprint Medicines
Moderator: Daryl Pritchard, PhD, Senior Vice President, Personalized Medicine Coalition
Panelists: Gary Gustavsen, MS, Partner and Managing Director, Precision Medicine, Health Advances ; Catherine Hajek, MD, Associate Professor of Medicine, USD Sanford School of Medicine and Medical Director, Sanford Imagenetics; Damon Hostin, MS, Lead, Health Systems, Market Access, Illumina; Luca Quagliata, PhD, Vice President and Global Head of Medical Affairs, Clinical NGS and Oncology Division, Thermo Fisher Scientific; Byeong Yoon, PhD, Executive Director, Oncology Global Medical Affairs, Amgen
During this session, experts in precision diagnostics, targeted therapy and healthcare delivery will discuss a first-of-its-kind landscape analysis applying a quantitative multi-factorial framework to assess the clinical adoption of personalized medicine in health care throughout the United States. Based on a survey of a representative sample of 153 health care providers, the analysis , which was commissioned by the Personalized Medicine Coalition, shows that 83 percent of the institutions studied scored a two or higher on the five-point scale used to examine their integration efforts. The study also showed that only 22 percent of the institutions studied scored a four or a five on the personalized medicine integration scale. Panelists will discuss this system-wide but incomplete push to implement personalized medicine in clinical settings, highlighting both the momentum that the field has as well as the limitations associated with the utilization of new precision medicine technologies and practices with extraordinary but understudied potential benefits.